Trial Profile
A Single-centre, Randomised, Double-blind, placebo-controlled, single-dose study to evaluate the pharmacokinetics, safety, and tolerability of Alicapistat (50, 100, 200, 400, 700, and 1000 mg) in Healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Aug 2018
Price :
$35
*
At a glance
- Drugs Alicapistat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- 21 Aug 2018 New trial record